INmune Bio (NASDAQ:INMB – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.14, Zacks reports.
INmune Bio Trading Down 0.6 %
INMB stock traded down $0.04 during midday trading on Friday, hitting $7.37. The stock had a trading volume of 126,609 shares, compared to its average volume of 241,440. INmune Bio has a 52 week low of $4.32 and a 52 week high of $12.72. The stock has a 50-day simple moving average of $8.39 and a 200 day simple moving average of $6.37. The firm has a market capitalization of $195.87 million, a price-to-earnings ratio of -3.36 and a beta of 1.93.
Analyst Ratings Changes
Several research analysts have commented on the company. Rodman & Renshaw started coverage on INmune Bio in a research report on Tuesday, January 28th. They issued a “buy” rating and a $23.00 price target on the stock. Maxim Group boosted their target price on shares of INmune Bio from $22.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Scotiabank increased their price target on shares of INmune Bio from $22.00 to $23.00 and gave the company a “sector outperform” rating in a report on Tuesday, February 11th. Finally, RODMAN&RENSHAW upgraded shares of INmune Bio to a “strong-buy” rating in a research report on Tuesday, January 28th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $22.80.
INmune Bio Company Profile
INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
See Also
- Five stocks we like better than INmune Bio
- There Are Different Types of Stock To Invest In
- Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback
- How to Use High Beta Stocks to Maximize Your Investing Profits
- JPMorgan: The ‘NVIDIA of Banking’ Poised for More Gains?
- Differences Between Momentum Investing and Long Term Investing
- Buy the Chewy Stock Reversal? Here’s Why Now Is the Time
Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.
